AstraZeneca Presents Tagrisso (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases 
Tagrisso extended the length of time patients with CNS metastases lived without disease worsening or death versus chemotherapy (11.7 vs 5.6 months) in the AURA3 trial